炎症小体在免疫检查点抑制剂抗肿瘤治疗中的研究进展

Research progress of inflammasome in anti-tumor therapy with immune checkpoint inhibitors

免疫检查点抑制剂(immune checkpoint inhibitors,ICIs)显著提高了肿瘤患者的生存率,但在不同类型的肿瘤中治疗效果不尽相同,如何提高免疫治疗抗肿瘤疗效和减轻免疫相关不良反应显得至关重要。固有免疫反应在ICIs抗肿瘤治疗中发挥重要作用。炎症通路既可以增强又可以减弱免疫治疗的疗效。本综述主要关注两个参与固有免疫和适应性免疫反应的关键因素,即炎症小体和免疫检查点,讨论炎症小体的激活如何影响ICIs的疗效及参与免疫相关不良反应的过程,从而寻找针对潜在靶点的治疗药物来增强抗肿瘤免疫治疗的疗效,并减轻不良反应。

Immune checkpoint inhibitors(ICIs)can significantly improve the overall survival rate of cancer patients.However,the effects vary in different tumor types.Identifying pathways to improve the anti-tumor efficacy of immunotherapy and reduce immune-related adverse reactions is important.Recent studies have demonstrated the importance of the innate immune response in anti-tumor therapy with ICIs.Inflammatory pathways can both improve and impair anti-tumor immunity.In this review,we focus on two factors involved in innate immunity and adaptive immune response:the inflammasome and immune checkpoints.We aimed to discuss how inflammasome activation can influence the clinical outcomes of administering ICIs and immune-related adverse reactions.This review will inform the search for targeted therapies,enhancing the efficacy of anti-tumor immunotherapy and reducing immune-related adverse reactions.